IP Library Granted Patent US 8,008,036
Granted Patent B2
US 8,008,036 · App. 12/238,415 · Granted Aug 30, 2011

Method for identifying autistic individuals amenable to digestive enzyme therapy

Assignee: Curemark, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,008,036
App. No.
12/238,415
Granted
Aug 30, 2011
Kind
B2
Abstract

A method for confirming a diagnosis of autism in an individual comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and comparing the quantitative level of fecal chymotrypsin in the stool sample of the person having autism to a stool sample from an individual that has a normal fecal chymotrypsin level and does not have autism and confirming a diagnosis of autism based on the measurement of the quantitative level of fecal chymoptrypsin.

Claims (37)

1. A method of identifying a person diagnosed with autism as being a candidate for treatment with digestive enzymes, comprising:

obtaining a stool sample from the person diagnosed with autism;

measuring a level of fecal chymotrypsin from the stool sample;

comparing the level of fecal chymotrypsin in the stool sample from the person to a normal level of fecal chymotrypsin; and

identifying that the person is a candidate for treatment with digestive enzymes if the level of fecal chymotrypsin in the stool sample from the person is less than the normal level of fecal chymotrypsin.

2. The method of claim 1 , wherein the normal level of fecal chymotrypsin is approximately 8.4 U/gram.

3. The method of claim 1 , wherein the level of fecal chymotrypsin in the stool sample from the person is considered subnormal if the level is below 8.4 U/gram.

4. The method of claim 1 , wherein the level of fecal chymotrypsin in the stool sample from the person is indicative of abnormal protein digestion if the level is below 8.4 U/gram.

5. The method of claim 1 , wherein the person has abnormal protein digestion.

6. The method of claim 1 , wherein the level of fecal chymotrypsin in the stool sample from the person indicates a lack of trypsin activity if the level is below 8.4 U/gram.

7. The method of claim 1 wherein the level of fecal chymotrypsin in the stool sample from the person indicates a lack of conversion of chymotrypsinogen to chymotrypsin if the level is below 8.4 U/gram.

8. The method of claim 1 wherein the level of fecal chymotrypsin in the stool sample from the person indicates a lack of amino acids required for growth and development if the level is below 8.4 U/gram.

9. The method of claim 1 , wherein the level of fecal chymotrypsin in the stool sample from the person is considered abnormal if the level is 4.2 U/gram and below.

10. The method of claim 1 , wherein the level of fecal chymotrypsin in the stool sample from the person is indicative of abnormal protein digestion if the level is 4.2 U/gram and below.

11. The method of claim 1 wherein the level of fecal chymotrypsin in the stool sample from the person indicates a lack of trypsin activity if the level is 4.2 U/gram and below.

12. The method of claim 1 wherein the level of fecal chymotrypsin in the stool sample from the person indicates a lack of conversion of chymotrypsinogen to chymotrypsin if the level is 4.2 U/gram and below.

13. The method of claim 1 , wherein the level of fecal chymotrypsin in the stool sample from the person indicates a lack of amino acids required for growth and development if the level is 4.2 U/gram and below.

14. The method of claim 1 , wherein the person exhibits a plurality of symptoms associated with autism.

15. The method of claim 1 , wherein the level of fecal chymotrypsin in the stool sample from the person is measured by photospectrometry.

16. A method of identifying a child diagnosed with autism as being a candidate for treatment with digestive enzymes, comprising:

obtaining a stool sample from the child diagnosed with autism;

measuring a level of fecal chymotrypsin from the stool sample;

comparing the level of fecal chymotrypsin in the stool sample from the child to a reference value of approximately 8.4 U/gram; and

identifying that the child is a candidate for treatment with digestive enzymes if the level of fecal chymotrypsin in the stool sample from the child is less than the reference value is lower than.

17. The method of claim 16 , wherein the level of fecal chymotrypsin in the stool sample from the child is considered subnormal if the level is below 8.4 U/gram.

18. The method of claim 16 , wherein the level of fecal chymotrypsin in the stool sample from the child is indicative of abnormal protein digestion if the level is below 8.4 U/gram.

19. The method of claim 16 , wherein the child has abnormal protein digestion.

20. The method of claim 16 , wherein the level of fecal chymotrypsin in the stool sample from the child indicates a lack of trypsin activity if the level is below 8.4 U/gram.

21. The method of claim 16 wherein the level of fecal chymotrypsin in the stool sample from the child indicates a lack of conversion of chymotrypsinogen to chymotrypsin if the level is below 8.4 U/gram.

22. The method of claim 16 wherein the level of fecal chymotrypsin in the stool sample from the child indicates a lack of amino acids required for growth and development if the level is below 8.4 U/gram.

23. The method of claim 16 , wherein the level of fecal chymotrypsin in the stool sample from the child is considered abnormal if the level is 4.2 U/gram and below.

24. The method of claim 16 , wherein the level of fecal chymotrypsin in the stool sample from the child is indicative of abnormal protein digestion if the level is 4.2 U/gram and below.

25. The method of claim 16 wherein the level of fecal chymotrypsin in the stool sample from the child indicates a lack of trypsin activity if the level is 4.2 U/gram and below.

26. The method of claim 16 wherein the level of fecal chymotrypsin in the stool sample from the child indicates a lack of conversion of chymotrypsinogen to chymotrypsin if the level is 4.2 U/gram and below.

27. The method of claim 16 , wherein the level of fecal chymotrypsin in the stool sample from the child indicates a lack of amino acids required for growth and development if the level is 4.2 U/gram and below.

28. The method of claim 16 , wherein the child exhibits a plurality of symptoms associated with autism.

29. The method of claim 16 , wherein the level of fecal chymotrypsin in the stool sample from the child is measured by photospectrometry.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2009
From: FALLON, JOAN M.
To: CUREMARK LLC
Reel/Frame 023182/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2009
From: FALLON, JOAN M.
To: CUREMARK, LLC
Reel/Frame 022626/0948 →
Continuity (5)
Continuation 11213382 · Oct 27, 2005
Division 10681018 · Oct 8, 2003
Continuation 09707395 · Nov 7, 2000
Continuation In Part 09466559 · Dec 17, 1999
Related Publication 20090197289A1 · Aug 6, 2009